MXPA06006377A - Metodos para modular la actividad de citocina y reactivos relacionados. - Google Patents

Metodos para modular la actividad de citocina y reactivos relacionados.

Info

Publication number
MXPA06006377A
MXPA06006377A MXPA06006377A MXPA06006377A MXPA06006377A MX PA06006377 A MXPA06006377 A MX PA06006377A MX PA06006377 A MXPA06006377 A MX PA06006377A MX PA06006377 A MXPA06006377 A MX PA06006377A MX PA06006377 A MXPA06006377 A MX PA06006377A
Authority
MX
Mexico
Prior art keywords
mouse
antagonist
cell
agonist
antibody
Prior art date
Application number
MXPA06006377A
Other languages
English (en)
Spanish (es)
Inventor
Wa Al Malefyt Rene De
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA06006377A publication Critical patent/MXPA06006377A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA06006377A 2003-12-03 2004-12-01 Metodos para modular la actividad de citocina y reactivos relacionados. MXPA06006377A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52655803P 2003-12-03 2003-12-03
PCT/US2004/040155 WO2005060998A2 (en) 2003-12-03 2004-12-01 Methods of modulating cytokine activity; related reagents

Publications (1)

Publication Number Publication Date
MXPA06006377A true MXPA06006377A (es) 2006-08-23

Family

ID=34710051

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06006377A MXPA06006377A (es) 2003-12-03 2004-12-01 Metodos para modular la actividad de citocina y reactivos relacionados.

Country Status (6)

Country Link
US (2) US20050142108A1 (https=)
EP (1) EP1706421A2 (https=)
JP (1) JP2007513163A (https=)
CA (1) CA2549306A1 (https=)
MX (1) MXPA06006377A (https=)
WO (1) WO2005060998A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852588B2 (en) * 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
CN107249630A (zh) * 2014-11-24 2017-10-13 国家健康与医学研究院 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重
GB2543729A (en) * 2015-04-28 2017-05-03 Argen-X N V Antibodies to IL-24
WO2021086997A1 (en) * 2019-10-28 2021-05-06 LBL Biotechnology Inc. Treating tissue fibrosis and/or injury and-or organ failure with interleukin 24 or interleukin 20 antagonist

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
EP2065396A1 (en) * 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
US20020072089A1 (en) * 1999-11-23 2002-06-13 Holtzman Douglas A. Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
WO2001055170A1 (en) * 2000-01-26 2001-08-02 Vanderbilt University Mob-5/hmob-5 as a cancer diagnostic marker
US20030100713A1 (en) * 2000-07-25 2003-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030023033A1 (en) * 2001-07-26 2003-01-30 Laure Dumoutier Novel class II cytokine receptors and uses thereof
US7157558B2 (en) * 2001-06-01 2007-01-02 Genentech, Inc. Polypeptide encoded by a polynucleotide overexpresses in tumors
US6902930B2 (en) * 2001-08-29 2005-06-07 Vanderbilt University Human Mob-5 (IL-24) receptors and uses thereof
CA2466229A1 (en) * 2001-11-06 2003-10-30 Eli Lilly And Company Use of il-19, il-22 and il-24 to treat hematopoietic disorders
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
US20040076606A1 (en) * 2002-09-14 2004-04-22 Ming-Shi Chang Methods of modulating inflammation by administration of interleukin-19 and inhibitors of IL-19 binding

Also Published As

Publication number Publication date
JP2007513163A (ja) 2007-05-24
CA2549306A1 (en) 2005-07-07
WO2005060998A2 (en) 2005-07-07
US20050142108A1 (en) 2005-06-30
WO2005060998A3 (en) 2006-03-16
EP1706421A2 (en) 2006-10-04
US20080226631A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
JP4605798B2 (ja) Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
EP1901768B1 (en) Methods of modulating il-23 activity; related reagents
JP4949859B2 (ja) インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用
US20090092604A1 (en) Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity
AU2005277236A1 (en) Methods and compositions for treating allergic inflammation
US20050214296A1 (en) Methods of modulating cytokine activity; related reagents
EP2292758A2 (en) Uses of mammalian cytokine; related reagents
US20080226631A1 (en) Methods of modulating cytokine activity; related reagents
WO2013070563A1 (en) Treatment of autoimmune and inflammatory disorders by inhibition of blimp-1
MXPA06009438A (en) Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
HK1152487A (en) Use for interleukin-33 (il-33) and the il-33 receptor complex